Angeles Duran

Angeles Duran

Auto-generated profile, based on publicly available information

Angeles Duran

Department of Pathology and Laboratory Medicine and Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
SCShankha S. Chatterjee
Shankha S. Chatterjee
JLJuan F. Linares
Juan F. Linares
TCTania Cid-Diaz
Tania Cid-Diaz
ADAngeles Duran
Angeles Duran
MKMohd. Imran K. Khan
Mohd. Imran K. Khan
MDMaria T. Diaz-Meco
Maria T. Diaz-Meco
Overcoming resistance to therapy is a major challenge in castration-resistant prostate cancer (CRPC). Lineage plasticity towards a neuroendocrine phenotype enables CRPC to adapt and survive targeted therapies. However, the molecular mechanisms of epigenetic reprogramming during this process are still poorly understood. Here we show that the protein kinase PKCλ/ι-mediated phosphorylation of enhancer of zeste homolog 2 (EZH2) regulates its proteasomal degradation and maintains EZH2 as part of the canonical polycomb repressive complex (PRC2). Loss of PKCλ/ι promotes a switch during enzalutamide treatment to a non-canonical EZH2 cistrome that triggers the transcriptional activation of the translational machinery to induce a transforming growth factor β (TGFβ) resistance program. The increased reliance on protein synthesis creates a synthetic vulnerability in PKCλ/ι-deficient CRPC.

30 June 2025 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
LALaura Antonucci
Laura Antonucci
NLNa Li
Na Li
ADAngeles Duran
Angeles Duran
ICIsidoro Cobo
Isidoro Cobo
CNChiara Nicoletti
Chiara Nicoletti
MKMichael Karin
Michael Karin